The Institute has developed a biomedical cell product (BCP) based on monocyte-derived dendritic cells and methods of cellular immunotherapy of oncological diseases and the prevention of relapses in patients with oncological diseases using the developed BCP. The Institute offers services for the treatment of diseases using the developed BCP under an outsourcing agreement.

Human dendritic cells (DCs) are specialized and most potent antigen-presenting cells that play a critical role in the regulation of innate and acquired immune responses.

A biomedical cell product based on monocyte-derived dendritic cells for the treatment of cancer contains mature dendritic cells loaded with the antigen of the corresponding tumor. The main task of DCs is to activate immunity against the patient's tumor.

The biomaterial for the production of BCP is the patient's peripheral blood. Individual tumor antigens (the so-called tumor lysates) and (or) synthetic standardized tumor-associated antigens are used as antigenic material.

The critical advantage of BCP is the ability to induce an immune response to weak tumor antigens that were not previously recognized by the patient's immune system.

The clinical effect of one course of immunotherapy is manifested by the stabilization of the tumor process (in 40-50% of cases), sometimes with partial or complete regression (5-15%). Such an effect can last on average from 3 months to a year. The maximum clinical impact of such treatment can be expected if it is continuously carried out in an adjuvant mode after removal of the primary focus (after surgery) to prevent tumor recurrence and destroy invisible micrometastases.

The Institute offers clients services for the treatment of diseases using the developed BCP based on monocytic dendritic cells under an outsourcing agreement.

The use of BCP based on dendritic cells in cellular immunotherapy of oncological diseases increases the effectiveness of existing methods of treatment and medical prevention of disease recurrence, increases the duration of event-free survival and life of patients, reduces the cost of treating patients, reduces hospitalization times, and reduces losses from underutilization of labor resources.

Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:

FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.

Consumers interested in receiving services for the treatment of diseases using the developed BCP based on monocyte-derived dendritic cells under an outsourcing agreement.